Caribou Biosciences Reports Strong Phase 1 Data for Two CAR-T Therapies, Vispa-cel and CB-011, at EHA 2026

summarizeSummary

Caribou Biosciences announced positive long-term Phase 1 clinical trial data for its two lead allogeneic CAR-T cell therapies, vispa-cel and CB-011, demonstrating durable responses and manageable safety profiles in difficult-to-treat cancers.

check_boxKey Events

• Vispa-cel Phase 1 ANTLER Trial Data

  Reported 82% overall response rate (ORR), 67% complete response (CR) rate, and 17.1 months median progression-free survival (PFS) in 27 second-line LBCL patients, with a generally well-tolerated safety profile.

• FDA Alignment for Vispa-cel Phase 3

  The company has reached alignment with the FDA on the design of the pivotal ANTLER-3 Phase 3 clinical trial for vispa-cel.

• CB-011 Phase 1 CaMMouflage Trial Data

  Showed 92% ORR, 83% CR rate, and 50% of patients in complete response at 15 months in 12 BCMA-naïve multiple myeloma patients, with a manageable safety profile.

• CB-011 Efficacy in Prior CAR-T Failure

  A patient who failed prior autologous CAR-T therapy achieved an ongoing complete response with CB-011.

auto_awesomeAnalysis

This filing is highly important as it provides strong, durable clinical data for Caribou Biosciences' two lead allogeneic CAR-T cell therapy candidates, vispa-cel and CB-011. The positive Phase 1 results, including high response rates and extended progression-free survival, suggest significant therapeutic potential in relapsed or refractory B-cell non-Hodgkin lymphoma and multiple myeloma. Crucially, the FDA alignment for vispa-cel's pivotal Phase 3 trial de-risks its development pathway, while CB-011's efficacy in a patient who failed prior autologous CAR-T highlights its potential in a challenging patient population. These results validate Caribou's CRISPR genome-editing platform and could significantly advance its pipeline, providing a strong foundation for future development and potential commercialization.